EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines Journal Article


Authors: Chakravarty, D.; Pedraza, A. M.; Cotari, J.; Liu, A. H.; Punko, D.; Kokroo, A.; Huse, J. T.; Altan-Bonnet, G.; Brennan, C. W.
Article Title: EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines
Abstract: Concurrent amplifications of EGFR and PDGFRA have been reported in up to 5% of glioblastoma (GBM) and it remains unclear why such independent amplification events, and associated receptor overexpression, would be adaptive during glioma evolution. Here, we document that EGFR and PDGFRA protein co-expression occurs in 37% of GBM. There is wide cell-to-cell variation in the expressions of these receptor tyrosine kinases (RTKs) in stable tumor sphere lines, frequently defining tumor cell subpopulations with distinct sensitivities to growth factors and RTK inhibitors. We also find evidence for functional transactivation of PDGFRA by EGFR and EGF-induced receptor heterodimerization, both of which are abolished by EGFR inhibitors. These results indicate that GBM growth responses to targeted therapies previously tested in clinical trials are strongly influenced by the balance of EGFR and PDGFRA activation in individual cells, which is heterogeneous at baseline. © 2017 The Author(s).
Journal Title: Scientific Reports
Volume: 7
ISSN: 2045-2322
Publisher: Nature Publishing Group  
Date Published: 2017-08-22
Start Page: 9043
Language: English
DOI: 10.1038/s41598-017-08940-9
PROVIDER: scopus
PMCID: PMC5567352
PUBMED: 28831081
DOI/URL:
Notes: Article -- Export Date: 2 October 2017 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Cameron Brennan
    226 Brennan
  2. Jason T Huse
    143 Huse
  3. Alicia Maria Pedraza
    26 Pedraza
  4. Jesse Coward
    14 Coward